DXCM

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Ro KhannaDemocrat $8.0k BuyApr 13, 2026 $1k-$15k -- --
John BoozmanRepublican $8.0k BuyJan 26, 2026 $1k-$15k -- --

Insider Trades

Name	Value	Action	Price	Current Price
Coleman JonEVP, Chief Commercial Officer $364k4.9k shares SellJun 4, 2026 $74.13 --
Coleman JonEVP, Chief Commercial Officer $359k4.9k shares SellJun 3, 2026 $73.00 --
Sayer Kevin RDirector, Officer: Executive Chair $1.9M26.8k shares SellMay 21, 2026 $72.00 --
Brown Michael JonEVP, Chief Legal Officer $102k1.7k shares SellMay 15, 2026 $59.91 --
Heller Bridgette PDirector $61k1k shares SellMay 12, 2026 $60.01 --
Brown Michael JonEVP, Chief Legal Officer $107k1.7k shares SellApr 15, 2026 $63.04 --

News

barrons.comLiving Longer Is Big Business. These Stocks Will Benefit.barrons.comJun 18

marketbeat.com3 Stocks Doing the Heavy Lifting in Healthcare's Reboundmarketbeat.comJun 18

forbes.comThe Healthcare M&A Waveforbes.comJun 17

zacks.comDXCM Receives FDA Clearance for Stelo OTC CGM System for Childrenzacks.comJun 16

zacks.comHere's Why DexCom (DXCM) is a Strong Growth Stockzacks.comJun 16

Trade DXCM

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

CEO: Jacob Steven Leach
IPO Date: Apr 14, 2005

Market Data

Open: $73.35
High: $75.44
Low: $72.52
Volume: 4.7M
52W High: $89.98
52W Low: $54.11

Valuation

Market Cap: $28B
Enterprise Value: $28B

Financials

Free Cash Flow: $1.1B
Revenue: $4.7B
Net Income: $836M
Cash: $918M
Debt: $1.4B

Events

EarningsJul 29

EPS est. 0.6